{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010112","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.812266+00:00","generated_at":"2026-06-17T12:50:52.701595+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Viking Therapeutics initiates Phase 1 study for oral GLP-1/GIP agonist VK2735; data expected H2 2023","bullets":["Phase 1 trial of oral VK2735 tablet, dual GLP-1/GIP receptor agonist, in healthy adults with BMI ≥30.","Randomized, double-blind, placebo-controlled study evaluating daily oral doses for 28 days.","Primary objective: safety and tolerability; exploratory measures include body weight and plasma glucose.","Top-line data anticipated in the second half of 2023.","Prior subcutaneous Phase 1 showed up to 7.8% mean weight loss; Phase 2 for subcutaneous formulation planned for mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010112","json":"https://secwatch.observer/filing/0000950170-23-010112.json","markdown":"https://secwatch.observer/filing/0000950170-23-010112.md","text":"https://secwatch.observer/filing/0000950170-23-010112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023010112/0000950170-23-010112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017023010112/vktx-20230328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:50:52.701595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}